ErasmusMC
Rotterdam, 3015 GD, Netherlands
Location status: Recruiting
Location contact
Marieke Wouters, PhD
PRINCIPAL_INVESTIGATOR
Mylène Bohmer, PhD
CONTACT
NCT Number: NCT06215235
Many adults with intellectual disabilities (ID) have depressive symptoms, which negatively impact their quality of life. A lot of of the non-medicinal forms of treatment are not or hardly suitable for people with ID. Bright light therapy (BLT) seems to be a good option. Earlier research has shown that BLT is applicable in this group and seems promising in terms of reducing depressive symptoms, without serious side effects.
In part 1 of this project we investigate the implementation of BLT at Amarant. We will take the lessons learned into part 2 of this project: the implementation of BLT at Abrona. We will evaluate this process and the outcomes.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Rotterdam, 3015 GD, Netherlands
Location status: Recruiting
Marieke Wouters, PhD
PRINCIPAL_INVESTIGATOR
Mylène Bohmer, PhD
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
for 2 weeks the patient will take place for a 10.000lux lamp for 20-30 minutes.
Time frame: three times during study, 3-4 months in between
Acceptability (Proctor et al., 2011) is the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. This will be measured by interviews.
Time frame: three times during study, 3-4 months in between
Appropriateness (Proctor et al., 2011) is the perceived fit, relevance, or compatibility of the innovation or evidence based practice for a given practice setting, provider, or consumer; and/or perceived fit of the innovation to address a particular issue or problem. This will be measured by interviews.
Time frame: three times during study, 3-4 months in between
Feasibility (Proctor et al., 2011) is defined as the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting. This will be measured by interviews.
Time frame: three times during study, 3-4 months in between
Fidelity (Proctor et al., 2011) is defined as the degree to which an intervention was implemented as it was prescribed in the original protocol or as it was intended by the program developers. This will be measured by interviews and by case report study.
Time frame: three times during study, 3-4 months in between
Implementation strategies are methods to enhance the adoption, implementation and sustainability of a policy or intervention. This will be studied with interview data and logs.
Time frame: three times during study, 3-4 months in between
Barriers and facilitators to BLT, measured by interviews using the Consolidated Framework for Implementation Research (CFIR, Damschroder et al., 2009)
Time frame: 1 year
Depressive symptoms measured by the Anxiety, Depression, and Mood Scale (ADAMS, Hermans et al., 2008). It contains 28 items, each can be scored 0 to 3. Minimum score 0 and maximum score 84 and higher scores mean worse outcome.
Time frame: 1 year
Behaviour that could be linked to depressive symptoms measured by the Aberrant Behaviour Checklist (ABC, Aman et al., 1985). It contains 58 items, each can be scored 0 to 3. Minimum score 0 and maximum score 174. Higher score means worse outcome.
Erasmus Medical Center
Other
Alleviation of Depressive Symptoms in People With Intellectual Disabilities
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06462196
Analgesics, Anesthetics
Bethesda, Maryland, United States
View Trial DetailsNCT07719517
Behavior, Behavioral Symptoms
Hong Kong
View Trial DetailsNCT07228520
Aging, Behavior
Baltimore, Maryland, United States
View Trial DetailsNCT07717385
Anxiety Disorders, Anxiety Symptoms
New York, United States
View Trial Details